ClinicalTrials.gg
TerminatedNCT05556343MERCUTIOUpdated Jun 2, 2026Results posted

A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

A Phase 2 interventional study of MYK-224 in Cardiomyopathy, Hypertrophic, sponsored by Bristol-Myers Squibb. Terminated at 25 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Why this study was terminated
Business objectives have changed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb — 9 open to participants now, 14 under way, 1 of them phase 3. Cardiomyopathy, Hypertrophic · Bristol-Myers Squibb.

Enrollment
14th of 16
18 · median 55
Started
2023
with 6 others
Phase 2
4 of 31
none open now
Registered
13th of 31
by date

Among the 31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, this one is the 14th largest by enrollment of the 16 interventional ones that give a count, is one of 7 that started in 2023, is one of 4 in phase 2, and was the 13th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

9 of the 31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MYK-224 in participants with obstructive Hypertrophic Cardiomyopathy (oHCM)

03

Conditions studied

  • Cardiomyopathy, Hypertrophic

Keywords

  • Obstructive Hypertrophic Cardiomyopathy
  • MYK-224
  • BMS-986435
  • HCM
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has adequate acoustic windows, to enable accurate TTEs as determined by the echocardiography core laboratory.
  • Men or women diagnosed with oHCM consistent with current American College of Cardiology Foundation/American Heart Association and European Society of Cardiology guidelines, satisfying both of the following criteria:

    • Has unexplained left ventricular (LV) hypertrophy with nondilated ventricular chambers in the absence of other cardiac (eg, hypertension, aortic stenosis) or systemic disease and with maximal LV wall thickness ≥ 15 millimeter (mm) (or ≥ 13 mm with positive family history of hypertrophic cardiomyopathy or with a known disease-causing mutation), as determined by core laboratory interpretation.

AND

-- Has a LVOT peak gradient during screening as assessed by echocardiography of ≥ 50 millimeters of mercury (mm Hg) at rest, or ≥ 30 mm Hg at rest and ≥ 50 mm Hg with Valsalva maneuver (confirmed by echocardiography core laboratory interpretation).

  • Has resting ≥ 60% at the Screening visit as determined by echocardiography core laboratory.
  • (NYHA) functional class II or III symptoms at screening.
  • Has a valid measurement of LVOT post-exercise peak gradient at screening as determined by echocardiography core laboratory.

Exclusion criteria

Exclusion Criteria:

  • Presence of any medical condition that precludes exercise stress testing.
  • History of syncope or sustained ventricular tachyarrhythmia within 6 months prior to screening.
  • Known infiltrative or storage disorder causing cardiac hypertrophy that mimics HCM, such as Fabry disease, amyloidosis, or Noonan syndrome with left ventricular hypertrophy.
  • Prior treatment with mavacamten or aficamten. An exception may be made in cases where myosin inhibitor use was not within 4 months of the Screening visit, and with the agreement of both the Investigator and the Medical Monitor.
  • Has been successfully treated with invasive septal reduction (surgical myectomy or percutaneous alcohol septal ablation [ASA]) within 6 months prior to Screening or plans to have either of these treatments during the study (Note: Individuals with an unsuccessful myectomy or percutaneous ASA procedure performed > 6 months prior to Screening may be enrolled if study eligibility criteria for LVOT gradient criteria are met).
  • Implantable cardioverter-defibrillator (ICD) placement or pulse generator change within 2 months prior to screening or planned new ICD placement during the study (pulse generator changes, if needed during the study are allowed).
  • Has a history of resuscitated sudden cardiac arrest (any time) or known history of appropriate implantable cardioverter-defibrillator (ICD discharge for life-threatening ventricular arrhythmia within 6 months prior to screening.
  • Has paroxysmal, atrial fibrillation with atrial fibrillation present per the Investigator's evaluation of the participant's at the time of Screening.
  • Has persistent or permanent atrial fibrillation not on anticoagulation for at least 4 weeks prior to Screening and/or not adequately rate controlled within 6 months prior to Screening (Note: Participants with persistent or permanent atrial fibrillation who are anticoagulated and adequately rate-controlled are allowed).
  • Has with Fridericia correction (QTcF) > 500 msec when QRS interval \< 120 msec or QTcF > 520 msec when QRS ≥ 120 msec if participant has left bundle branch block or any other 12-lead ECG abnormality considered by the investigator to pose a risk to participant safety (eg, second-degree atrioventricular block type II).
  • Has known moderate or severe (per investigator's judgment) aortic valve stenosis at screening.
  • History of LV systolic dysfunction ( \< 45%) at any time during their clinical course.
  • pulmonary disease associated with exertional dyspnea.
  • Has known significant unrevascularized obstructive coronary artery disease (>70% stenosis in one or more main epicardial coronary arteries) or history of myocardial infarction Note: participants with prior coronary artery bypass grafting (CABG) or percutaneous coronary interventions (PCIs) are allowed if the procedure was performed at least 12 weeks prior to screening
  • Prior treatment with cardiotoxic agents such as anthracyclines (eg, doxorubicin) or similar

Other protocol-defined criteria apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants will receive MYK-224 either as a monotherapy or in combination with standard-of-care consisting of a beta-blocker. Participants who complete Cohort 1 will be eligible for an optional open label extension period

    Drug: MYK-224

  • Experimental
    Cohort 2

    Participants will receive MYK-224 in combination with standard-of-care consisting of either a calcium channel blocker or disopyramide (which is given in combination with either a beta-blocker or calcium channel blocker). Participants who complete Cohort 2 will be eligible for an optional open label extension period

    Drug: MYK-224

Interventions

  • Specified dose on specified days

    Also known as: BMS-986435

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With Adverse Events and Serious Adverse Events

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization.

    Time frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)

  2. Part A: Number of Participants With at Least One Event of Arrhythmias

    Arrhythmias included atrial fibrillation/flutter (new from screening and recurrent), ventricular tachyarrhythmias (ventricular tachycardia, ventricular fibrillation, and Torsades de Pointe).

    Time frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)

  3. Part A: Number of Participants With at Least One Event of Appropriate Implantable Cardioverter Defibrillator Therapy and Resuscitated Cardiac Arrest

    Time frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)

  4. Part A: Change From Baseline in Vital Signs - Heart Rate

    Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Heart rate was measured in rested state.

    Time frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)

  5. Part A: Change From Baseline in Vital Signs - Mean Systolic Blood Pressure

    Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Systolic blood pressure was measured in rested state.

    Time frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)

  6. Part A: Change From Baseline in Vital Signs - Mean Diastolic Blood Pressure

    Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Diastolic blood pressure was measured in rested state.

    Time frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)

  7. Part A: Change From Baseline in Vital Signs - Respiratory Rate

    Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Respiratory rate was measured in rested state.

    Time frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)

  8. Part A: Change From Baseline in Vital Signs - Temperature

    Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224.

    Time frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)

  9. Part A: Change From Baseline in Vital Signs - Weight

    Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224.

    Time frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)

  10. Part A: Number of Participants With Abnormal Physical Examination Results

    The complete physical examination included weight and calculated BMI, a neurological examination (gross motor and deep tendon reflexes),and an assessment of the following: general appearance, skin, head and neck, mouth, lymph nodes, thyroid, abdomen, musculoskeletal, cardiovascular, neurological, and respiratory systems with other systems included, as directed by interval history.

    Time frame: Baseline and until study end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)

  11. Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Results

    Twelve-lead ECG evaluations will be performed in the supine position after 10 minutes of rest at Screening and at selected clinic visits prior to MYK-224 dosing and before any blood sample collection. QTc prolongation is defined by either the mean of QTcF \> 499 or mean of QTcB \> 499 according to the project requirement specification from Clario.

    Time frame: Baseline and until study end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)

  12. Part A: Number of Participants With Adverse Events Related to Clinical Laboratory Parameters (Hematology, Chemistry and Urinalysis)

    Blood samples were collected to assess the clinical laboratory parameters.

    Time frame: Baseline and untill end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)

  13. Part A:Percentage of Participants With Incidence of Symptomatic Left Ventricular Ejection Fraction (LVEF) < 50%

    LVEF was assessed using transthoracic echocardiogram (TTE) in resting state. 90% CIs are calculated based on Exact Binomial proportion test. LVEF value was calculated by Simpson Biplane method.

    Time frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)

  14. Part A: Percentage of Participants With Incidence of Symptomatic Left Ventricular Ejection Fraction (LVEF) <= 30%

    LVEF was assessed using transthoracic echocardiogram (TTE) in resting state. 90% CIs are calculated based on Exact Binomial proportion test. LVEF value was calculated by Simpson Biplane method.

    Time frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)

Secondary outcomes

  1. Part A: Aggregate Mean of Left Ventricular Ejection Fraction (LVEF)

    Time frame: Treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)

  2. Part A: Change From Baseline in Left Ventricular Ejection Fraction (LVEF)

    Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Participants with data available at the timepoint were included in the analysis.

    Time frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)

  3. Part A: Aggregate Mean of Left Ventricular Outflow Tract (LVOT) Peak Gradient (Post-Exercise, Resting, and Valsalva)

    Time frame: Treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)

  4. Part A: Change From Baseline in Left Ventricular Outflow Tract (LVOT) Peak Gradient (Post-Exercise, Resting, and Valsalva)

    Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Participants with data available at the timepoint were included in the analysis.

    Time frame: Treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)

  5. Part A: Percentage of Participants With Resting Left Ventricular Outflow Tract (LVOT) Peak Gradient < 30 mmHg and Valsalva LVOT Peak Gradient < 50 mmHg

    Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. 90%CIs are calculated based on Normal approximation.

    Time frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)

  6. Part A: Plasma Concentration of MYK-224

    Blood samples were collected to assess plasma concentration of MYK-224.

    Time frame: Pre-dose and 1 hour post-dose end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)

07

Results

Posted Jun 2, 2026

Participant flow

Part A - Dose Treatment
Participant flow — Part A - Dose Treatment
MilestonePart A - Dose Treatment - MYK-224Part B - Open Label Extension - MYK-224
Started180
Completed170
Not completed10
Withdrew: Other reasons10
Part B - Open Label Extension
Participant flow — Part B - Open Label Extension
MilestonePart A - Dose Treatment - MYK-224Part B - Open Label Extension - MYK-224
Started016
Completed00
Not completed016
Withdrew: Study terminated by sponsor016

Outcome measures

PrimaryPart A: Number of Participants With Adverse Events and Serious Adverse Events

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization.

Time frame:
From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Count of participants · Participants
Part A: Number of Participants With Adverse Events and Serious Adverse Events
ParticipantsPart A - Dose Treatment - MYK-224
Participants with at least one adverse events in Part A15
Participants with at least one serious adverse events in Part A0
PrimaryPart A: Number of Participants With at Least One Event of Arrhythmias

Arrhythmias included atrial fibrillation/flutter (new from screening and recurrent), ventricular tachyarrhythmias (ventricular tachycardia, ventricular fibrillation, and Torsades de Pointe).

Time frame:
From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Count of participants · Participants
Part A: Number of Participants With at Least One Event of Arrhythmias
ParticipantsPart A - Dose Treatment - MYK-224
Atrial Fibrillation/Flutter2
Ventricular Tachyarrhythmias1
PrimaryPart A: Number of Participants With at Least One Event of Appropriate Implantable Cardioverter Defibrillator Therapy and Resuscitated Cardiac Arrest
Time frame:
From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Count of participants · Participants
Part A: Number of Participants With at Least One Event of Appropriate Implantable Cardioverter Defibrillator Therapy and Resuscitated Cardiac Arrest
ParticipantsPart A - Dose Treatment - MYK-224
Part A: Number of Participants With at Least One Event of Appropriate Implantable Cardioverter Defibrillator Therapy and Resuscitated Cardiac Arrest1
PrimaryPart A: Change From Baseline in Vital Signs - Heart Rate

Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Heart rate was measured in rested state.

Time frame:
Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Mean · beats per minute
Part A: Change From Baseline in Vital Signs - Heart Rate
beats per minutePart A - Dose Treatment - MYK-224
Part A: Change From Baseline in Vital Signs - Heart Rate0.9 ± 8.96
PrimaryPart A: Change From Baseline in Vital Signs - Mean Systolic Blood Pressure

Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Systolic blood pressure was measured in rested state.

Time frame:
Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Mean · mmHg
Part A: Change From Baseline in Vital Signs - Mean Systolic Blood Pressure
mmHgPart A - Dose Treatment - MYK-224
Part A: Change From Baseline in Vital Signs - Mean Systolic Blood Pressure2.5 ± 18.25
PrimaryPart A: Change From Baseline in Vital Signs - Mean Diastolic Blood Pressure

Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Diastolic blood pressure was measured in rested state.

Time frame:
Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Mean · mmHg
Part A: Change From Baseline in Vital Signs - Mean Diastolic Blood Pressure
mmHgPart A - Dose Treatment - MYK-224
Part A: Change From Baseline in Vital Signs - Mean Diastolic Blood Pressure4.2 ± 12.62
PrimaryPart A: Change From Baseline in Vital Signs - Respiratory Rate

Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Respiratory rate was measured in rested state.

Time frame:
Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Mean · breaths per minute
Part A: Change From Baseline in Vital Signs - Respiratory Rate
breaths per minutePart A - Dose Treatment - MYK-224
Part A: Change From Baseline in Vital Signs - Respiratory Rate0.6 ± 2.23
PrimaryPart A: Change From Baseline in Vital Signs - Temperature

Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224.

Time frame:
Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Mean · Celsius
Part A: Change From Baseline in Vital Signs - Temperature
CelsiusPart A - Dose Treatment - MYK-224
Part A: Change From Baseline in Vital Signs - Temperature-0.09 ± 0.280
PrimaryPart A: Change From Baseline in Vital Signs - Weight

Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224.

Time frame:
Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Mean · kilogram
Part A: Change From Baseline in Vital Signs - Weight
kilogramPart A - Dose Treatment - MYK-224
Part A: Change From Baseline in Vital Signs - Weight0.89 ± 3.168
PrimaryPart A: Number of Participants With Abnormal Physical Examination Results

The complete physical examination included weight and calculated BMI, a neurological examination (gross motor and deep tendon reflexes),and an assessment of the following: general appearance, skin, head and neck, mouth, lymph nodes, thyroid, abdomen, musculoskeletal, cardiovascular, neurological, and respiratory systems with other systems included, as directed by interval history.

Time frame:
Baseline and until study end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Count of participants · Participants
Part A: Number of Participants With Abnormal Physical Examination Results
ParticipantsPart A - Dose Treatment - MYK-224
Cardiovascular11
Skin1
Other1
PrimaryPart A: Number of Participants With Abnormal Electrocardiogram (ECG) Results

Twelve-lead ECG evaluations will be performed in the supine position after 10 minutes of rest at Screening and at selected clinic visits prior to MYK-224 dosing and before any blood sample collection. QTc prolongation is defined by either the mean of QTcF \> 499 or mean of QTcB \> 499 according to the project requirement specification from Clario.

Time frame:
Baseline and until study end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Count of participants · Participants
Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Results
ParticipantsPart A - Dose Treatment - MYK-224
QTC PROLONGATION (Baseline)3
QTC PROLONGATION (end date)2
ST DEPRESSION (Baseline)4
ST DEPRESSION (end date)2
T WAVES FLAT (Baseline)1
T WAVES FLAT (end date1
T WAVE INVERSION (Baseline)7
T WAVE INVERSION (end date)3
ATRIAL FIBRILLATION/FLUTTER (Baseline)5
ATRIAL FIBRILLATION/FLUTTER (End date)1
PrimaryPart A: Number of Participants With Adverse Events Related to Clinical Laboratory Parameters (Hematology, Chemistry and Urinalysis)

Blood samples were collected to assess the clinical laboratory parameters.

Time frame:
Baseline and untill end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Count of participants · Participants
Part A: Number of Participants With Adverse Events Related to Clinical Laboratory Parameters (Hematology, Chemistry and Urinalysis)
ParticipantsPart A - Dose Treatment - MYK-224
Chemistry (Elevated Alanine Aminotransferase)1
Chemistry (Transaminases increased)1
Hematology0
Urinalysis0
PrimaryPart A:Percentage of Participants With Incidence of Symptomatic Left Ventricular Ejection Fraction (LVEF) < 50%

LVEF was assessed using transthoracic echocardiogram (TTE) in resting state. 90% CIs are calculated based on Exact Binomial proportion test. LVEF value was calculated by Simpson Biplane method.

Time frame:
From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Number · percentage of participants
Part A:Percentage of Participants With Incidence of Symptomatic Left Ventricular Ejection Fraction (LVEF) < 50%
percentage of participantsPart A - Dose Treatment - MYK-224
Part A:Percentage of Participants With Incidence of Symptomatic Left Ventricular Ejection Fraction (LVEF) < 50%0 (0 to 0)
PrimaryPart A: Percentage of Participants With Incidence of Symptomatic Left Ventricular Ejection Fraction (LVEF) <= 30%

LVEF was assessed using transthoracic echocardiogram (TTE) in resting state. 90% CIs are calculated based on Exact Binomial proportion test. LVEF value was calculated by Simpson Biplane method.

Time frame:
From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Number · percentage of participants
Part A: Percentage of Participants With Incidence of Symptomatic Left Ventricular Ejection Fraction (LVEF) <= 30%
percentage of participantsPart A - Dose Treatment - MYK-224
Part A: Percentage of Participants With Incidence of Symptomatic Left Ventricular Ejection Fraction (LVEF) <= 30%0 (0 to 0)
SecondaryPart A: Aggregate Mean of Left Ventricular Ejection Fraction (LVEF)
Time frame:
Treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Mean · percentage
Part A: Aggregate Mean of Left Ventricular Ejection Fraction (LVEF)
percentagePart A - Dose Treatment - MYK-224
Part A: Aggregate Mean of Left Ventricular Ejection Fraction (LVEF)65.0 ± 4.09
SecondaryPart A: Change From Baseline in Left Ventricular Ejection Fraction (LVEF)

Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Participants with data available at the timepoint were included in the analysis.

Time frame:
Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Mean · percentage
Part A: Change From Baseline in Left Ventricular Ejection Fraction (LVEF)
percentagePart A - Dose Treatment - MYK-224
Part A: Change From Baseline in Left Ventricular Ejection Fraction (LVEF)0.1 ± 4.31
SecondaryPart A: Aggregate Mean of Left Ventricular Outflow Tract (LVOT) Peak Gradient (Post-Exercise, Resting, and Valsalva)
Time frame:
Treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Mean · mmHg
Part A: Aggregate Mean of Left Ventricular Outflow Tract (LVOT) Peak Gradient (Post-Exercise, Resting, and Valsalva)
mmHgPart A - Dose Treatment - MYK-224
Resting LVOT25.423 ± 23.5685
Valsalva LVOT43.888 ± 36.1765
Post-Exercise LVOT56.965 ± 45.1914
SecondaryPart A: Change From Baseline in Left Ventricular Outflow Tract (LVOT) Peak Gradient (Post-Exercise, Resting, and Valsalva)

Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Participants with data available at the timepoint were included in the analysis.

Time frame:
Treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Mean · mmHg
Part A: Change From Baseline in Left Ventricular Outflow Tract (LVOT) Peak Gradient (Post-Exercise, Resting, and Valsalva)
mmHgPart A - Dose Treatment - MYK-224
Resting LVOT-49.093 ± 30.9153
Valsalva LVOT-51.079 ± 36.1091
Post-Exercise LVOT-34.654 ± 43.1174
SecondaryPart A: Percentage of Participants With Resting Left Ventricular Outflow Tract (LVOT) Peak Gradient < 30 mmHg and Valsalva LVOT Peak Gradient < 50 mmHg

Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. 90%CIs are calculated based on Normal approximation.

Time frame:
Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Number · percentage of participants
Part A: Percentage of Participants With Resting Left Ventricular Outflow Tract (LVOT) Peak Gradient < 30 mmHg and Valsalva LVOT Peak Gradient < 50 mmHg
percentage of participantsPart A - Dose Treatment - MYK-224
Part A: Percentage of Participants With Resting Left Ventricular Outflow Tract (LVOT) Peak Gradient < 30 mmHg and Valsalva LVOT Peak Gradient < 50 mmHg61.1 (42.21 to 80.01)
SecondaryPart A: Plasma Concentration of MYK-224

Blood samples were collected to assess plasma concentration of MYK-224.

Time frame:
Pre-dose and 1 hour post-dose end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Reported as:
Geometric mean · ng/mL
Part A: Plasma Concentration of MYK-224
ng/mLPart A - Dose Treatment - MYK-224
MYK-224 Monotherapy - Pre-Dose189.113 ± 65.6285
MYK-224 Monotherapy, 1 hour Post-dose280.621 ± 49.9295
MYK-224 + Beta Blockers - Pre-Dose136.926 ± 111.1556
MYK-224 + Beta Blockers - 1 hour Post-dose199.685 ± 92.7083

Adverse events

Collected over All cause mortality and adverse events were collected from from first dose (Day 1) until study end date in Part A or B or 30 days after early termination date (Median 69.05 weeks and Maximum 85.0 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A - Dose Treatment - MYK-2240/18 (0%)0/18 (0%)15/18 (83.3%)
Part B - Open Label Extension - MYK-2240/16 (0%)3/16 (18.8%)6/16 (37.5%)
Most frequent serious events
Most frequent serious events
EventPart A - Dose Treatment - MYK-224Part B - Open Label Extension - MYK-224
EpilepsyNervous system disorders0/181/16
PresyncopeNervous system disorders0/181/16
DyspnoeaRespiratory, thoracic and mediastinal disorders0/181/16
Most frequent other events
Showing 10 of 52
Most frequent other events
EventPart A - Dose Treatment - MYK-224Part B - Open Label Extension - MYK-224
DyspnoeaRespiratory, thoracic and mediastinal disorders7/180/16
HeadacheNervous system disorders5/180/16
FatigueGeneral disorders4/181/16
InfluenzaInfections and infestations4/180/16
DizzinessNervous system disorders4/180/16
Atrial fibrillationCardiac disorders2/181/16
Chest discomfortGeneral disorders2/180/16
HypertensionVascular disorders2/181/16
Angina pectorisCardiac disorders1/181/16
Oedema peripheralGeneral disorders1/181/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part A - Dose Treatment - MYK-224
Mean59.8 ± 9.08
Sex: Female, Male
Sex: Female, Male(Participants)Part A - Dose Treatment - MYK-224
Female5
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A - Dose Treatment - MYK-224
Hispanic or Latino2
Not Hispanic or Latino14
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A - Dose Treatment - MYK-224
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White17
More than one race0
Unknown or Not Reported1
BACKGROUND HCM THERAPY
BACKGROUND HCM THERAPY(Participants)Part A - Dose Treatment - MYK-224
BETA BLOCKER USE AT BASELINE9
CALCIUM CHANNEL BLOCKER USE AT BASELINE0
DISOPYRAMIDE USE AT BASELINE0
NONE9
Implantable Cardioverter Defibrillator (ICD) Therapy Use
Implantable Cardioverter Defibrillator (ICD) Therapy Use(Participants)Part A - Dose Treatment - MYK-224
Yes5
No ICD use13
NYHA FUNCTIONAL CLASS
NYHA FUNCTIONAL CLASS(Participants)Part A - Dose Treatment - MYK-224
CLASS I1
CLASS II12
CLASS III5
CLASS IV0
LEFT VENTRICULAR EJECTION FRACTION
LEFT VENTRICULAR EJECTION FRACTION(percentage)Part A - Dose Treatment - MYK-224
Mean65.4 ± 4.23

6 further baseline measures are reported on the registry.

08

Study locations

25 sites
  • Local Institution - 0026
    La Jolla, California 92037, United States
  • Local Institution - 0014
    Los Angeles, California 90048, United States
  • Local Institution - 0016
    San Francisco, California 94158-2156, United States
  • Local Institution - 0001
    Kansas City, Kansas 66103-2937, United States
  • Local Institution - 0032
    New York, New York 10032-3802, United States
  • Local Institution - 0013
    Durham, North Carolina 27710, United States
  • Local Institution - 0031
    Cincinnati, Ohio 45267, United States
  • Local Institution - 0015
    Cleveland, Ohio 44195-0001, United States
  • Local Institution - 0024
    Portland, Oregon 97239-3011, United States
  • Local Institution - 0021
    Nashville, Tennessee 37205-2202, United States
  • Local Institution - 0025
    San Antonio, Texas 78229-3900, United States
  • Local Institution - 0006
    Salt Lake City, Utah 84132, United States
  • Local Institution - 0027
    Bologna, BO 40138, Italy
  • Local Institution - 0005
    Florence, FI 50134, Italy
  • Local Institution - 0029
    Milan, 20138, Italy
  • Local Institution - 0011
    Katowice, Silesian Voivodeship 40-555, Poland
  • Local Institution - 0030
    Wroclaw, 54-049, Poland
  • Local Institution - 0028
    Alicante, A 03010, Spain
  • Local Institution - 0022
    Granada, GR 18014, Spain
  • Local Institution - 0008
    Málaga, MA 29010, Spain
  • Local Institution - 0002
    El Palmar, MU 30120, Spain
  • Local Institution - 0003
    Valencia, V 46026, Spain
  • Local Institution - 0009
    A Coruña, 15006, Spain
  • Local Institution - 0023
    Barcelona, 08036, Spain
  • Local Institution - 0010
    Majadahonda, 28035, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Aug 2024, 19 months.

Results were first posted in Jun 2026, 1 year 9 months after primary completion. A results delay was requested in Aug 2025.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2022
First posted
Sep 27, 2022
StartActual
Jan 18, 2023
Primary completionActual
Aug 19, 2024
CompletionActual
Feb 27, 2025
Results delay requested
Aug 11, 2025
Results first posted
Jun 2, 2026
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05556343
Responsible party
Sponsor
First posted
Sep 27, 2022
Start date
Jan 18, 2023
Primary completion
Aug 19, 2024
Completion
Feb 27, 2025
Results posted
Jun 2, 2026
Last update
Jun 2, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delocamten

Start the discussion